Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial.
Wataya-Kaneda M, Nagai H, Ohno Y, Yokozeki H, Fujita Y, Niizeki H, Yoshida K, Ogai M, Yoshida Y, Asahina A, Fukai K, Tateishi C, Hamada I, Takahata T, Shimizu K, Shimasaki S, Murota H. Wataya-Kaneda M, et al. Among authors: shimizu k. Dermatol Ther (Heidelb). 2020 Aug;10(4):635-650. doi: 10.1007/s13555-020-00387-7. Epub 2020 May 8. Dermatol Ther (Heidelb). 2020. PMID: 32385845 Free PMC article.
Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers.
Inoue Y, Usui N, Hiroki T, Shimizu K, Kobayashi S, Shimasaki S. Inoue Y, et al. Among authors: shimizu k. Eur J Drug Metab Pharmacokinet. 2013 Jun;38(2):139-48. doi: 10.1007/s13318-012-0105-x. Epub 2012 Sep 12. Eur J Drug Metab Pharmacokinet. 2013. PMID: 22968854 Free PMC article. Clinical Trial.
Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
Wataya-Kaneda M, Ohno Y, Fujita Y, Yokozeki H, Niizeki H, Ogai M, Fukai K, Nagai H, Yoshida Y, Hamada I, Hio T, Shimizu K, Murota H. Wataya-Kaneda M, et al. Among authors: shimizu k. JAMA Dermatol. 2018 Jul 1;154(7):781-788. doi: 10.1001/jamadermatol.2018.1408. JAMA Dermatol. 2018. PMID: 29800026 Free PMC article. Clinical Trial.
Efficacy and safety of intravenous fosphenytoin for patients with acute herpes zoster-associated pain: A placebo-controlled randomized trial.
Iseki M, Yamamoto T, Ogawa Y, Majima Y, Abe Y, Watanabe D, Amaya F, Hasegawa T, Inafuku K, Kosugi T, Nomura Y, Deguchi T, Hamada T, Shimizu K, Arai S, Takahashi M, Hamada I, Ishikawa Y, Kawashima M. Iseki M, et al. Among authors: shimizu k. J Dermatol. 2024 Feb;51(2):234-242. doi: 10.1111/1346-8138.17054. Epub 2023 Dec 27. J Dermatol. 2024. PMID: 38149403 Clinical Trial.
Characteristics and outcomes of COVID-19 patients admitted to hospital with and without respiratory symptoms.
Citarella BW, Kartsonaki C, Ibáñez-Prada ED, Gonçalves BP, Baruch J, Escher M, Pritchard MG, Wei J, Philippy F, Dagens A, Hall M, Lee J, Kutsogiannis DJ, Wils EJ, Fernandes MA, Tirupakuzhi Vijayaraghavan BK, Panda PK, Martin-Loeches I, Ohshimo S, Fatoni AZ, Horby P, Dunning J, Rello J, Merson L, Rojek A, Vaillant M, Olliaro P, Reyes LF; ISARIC Clinical Characterisation Group. Citarella BW, et al. Heliyon. 2024 May 4;10(10):e29591. doi: 10.1016/j.heliyon.2024.e29591. eCollection 2024 May 30. Heliyon. 2024. PMID: 38779000 Free PMC article.
Hericenone C attenuates the second phase of formalin-induced nociceptive behavior by suppressing the accumulation of CD11c-positive cells in the paw epidermis via phosphorylated P65.
Li J, Hamamura K, Yoshida Y, Kawano S, Uchinomiya S, Xie J, Scuteri D, Fukuoka K, Zaitsu O, Tsurusaki F, Terada Y, Tsukamoto R, Nishi T, Fukuda T, Oyama K, Bagetta G, Ojida A, Shimizu K, Ohdo S, Matsunaga N. Li J, et al. Among authors: shimizu k. Biochem Biophys Res Commun. 2024 May 14;720:150077. doi: 10.1016/j.bbrc.2024.150077. Online ahead of print. Biochem Biophys Res Commun. 2024. PMID: 38759303 Free article.
7,177 results